News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Shirley Clayton Appointed Chief Executive Officer Of Abmaxis, Inc.

10/19/2005 5:09:58 PM

MOUNTAIN VIEW, Calif., Feb. 10 /PRNewswire/ -- Abmaxis, Inc., a privately held biopharmaceutical company, announced today that Shirley Liu Clayton has been named Chief Executive Officer. Abmaxis' proprietary technology allows for the discovery and development of human therapeutic antibodies through efficient molecular design and selection to significantly improve the efficacy of antibodies. The company can design de novo antibodies from an antigen or humanize antibodies from mice or other animals. Unlike current technologies that focus on one-dimensional sequences, Abmaxis focuses on three-dimensional structures as the means to design effective antibodies.

"I believe Abmaxis' technologies can be used to discover the best possible human monoclonal antibody and I am pleased to be joining the company at the point when the technology is ready for commercialization," stated Shirley Liu Clayton, Chief Executive Officer. "Along with my new colleagues, I am looking forward to partnering with biotech and pharmaceutical companies who can benefit from our technology. At the same time, we are also beginning the development of our own proprietary products."

"Shirley brings to Abmaxis a wealth of experience in guiding the growth of early stage biotechnology companies and is well qualified to lead the company to our next stage of growth," commented Peter Luo, Chief Technology Officer.

Ms. Clayton was most recently Chief Financial Officer of CBYON, a privately-held medical imaging company. Previously, she was the President, Chief Financial Officer and co-founder of Raven Biotechnologies, Inc., a cell biology company developing monoclonal antibody products. Ms. Clayton has held senior financial and executive officer positions in several other life science companies including Orquest, Inc., a medical technology company; TopoMetrix, a scientific instrument company; Cygnus, Inc., a drug delivery company; and Protein Design Labs, a monoclonal antibody company. She was at Genentech during most of the 1980's, as Vice President and Treasurer. Ms Clayton is on the board of the Bailard, Biehl and Kaiser Fund Group, a money management firm in San Mateo. She received her MBA from the Stanford University Graduate School of Business and her BS in Chemistry from Smith College.

Abmaxis is a venture-backed biopharmaceutical company dedicated to the discovery and development of the next generation of optimized human therapeutic antibodies. The company was founded in 2000 by three scientists who had worked together at Stanford, each bringing a unique expertise to the various stages of product discovery and development. Abmaxis is using its technology platform for the development of its own products and to collaborate with partners who are looking for optimally functional antibody products. The company is located in Mountain View, California. For additional information, please contact Shirley Clayton at 650 528-5120 ext. 130 or or visit the website:

Abmaxis, Inc.

CONTACT: Shirley Clayton, Chief Executive Officer, +1-650-528-5120, ext.130, or

Read at

comments powered by Disqus